1. Pink Sheet

Phase Zero: "Open for Business"

 
• By Ramsey Baghdadi

Despite a setback presented by a small micro-dosing trial in the UK, FDA says its "Phase Zero" program has appropriate safeguards in place and should be pursued by biopharmaceutical companies.

"Phase Zero" was supposed to be an important new tool for drug developers. Then a European trial went horribly wrong.

UK-based TeGenero AG is developing a monoclonal antibody (TGN 1412) for leukemia, rheumatoid arthritis and multiple sclerosis.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D